

Rabi Hanna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1205691/publications.pdf>

Version: 2024-02-01

79
papers

1,086
citations

567281

15
h-index

454955

30
g-index

79
all docs

79
docs citations

79
times ranked

1839
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2014, 124, 2596-2606.	1.4	228
2	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. <i>Journal of Clinical Oncology</i> , 2019, 37, 367-374.	1.6	110
3	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. <i>Blood</i> , 2018, 132, 1438-1451.	1.4	78
4	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. <i>Blood</i> , 2021, 138, 1429-1440.	1.4	54
5	Related and unrelated donor transplantation for β^2 -thalassemia major: results of an international survey. <i>Blood Advances</i> , 2019, 3, 2562-2570.	5.2	48
6	Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. <i>Haematologica</i> , 2019, 104, 1974-1983.	3.5	43
7	Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e65-e73.	2.0	40
8	Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 720-724.	2.0	39
9	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
10	Fractures in children with Pompe disease: a potential long-term complication. <i>Pediatric Radiology</i> , 2007, 37, 437-445.	2.0	28
11	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2015, 90, 144-148.	4.1	27
12	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2019, 54, 1281-1286.	2.4	24
13	Hematologic complications with age in Shwachman-Diamond syndrome. <i>Blood Advances</i> , 2022, 6, 297-306.	5.2	23
14	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1029-1034.	2.0	19
15	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1651-1656.	2.0	18
16	Synergistic Effect of Major Histocompatibility Complex Class I-Related Chain A and Human Leukocyte Antigen-DRB1 Mismatches in Association with Acute Graft-versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1835-1840.	2.0	17
17	Effect of bone marrow CD34+ cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 775-781.	2.4	14
18	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	1.2	13

#	ARTICLE	IF	CITATIONS
19	Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Venous-occlusive Disease with Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2017, 37, 707-714.	3.8	11
20	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1505-1510.	2.0	11
21	A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations. <i>Contemporary Clinical Trials Communications</i> , 2021, 21, 100733.	1.1	11
22	Invasive <i>Aspergillus</i> infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations. <i>Pharmacogenomics</i> , 2016, 17, 663-667.	1.3	10
23	A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. <i>Human Molecular Genetics</i> , 2022, 31, 3393-3404.	2.9	10
24	The association of histologic grade with acute graft-versus-host disease response and outcomes. <i>American Journal of Hematology</i> , 2017, 92, 683-688.	4.1	9
25	<i>Mycobacterium genavense</i> -induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature. <i>Transplant Infectious Disease</i> , 2017, 19, e12656.	1.7	9
26	Impact of germline CTC 1 alterations on telomere length in acquired bone marrow failure. <i>British Journal of Haematology</i> , 2019, 185, 935-939.	2.5	9
27	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2019, 3, 2732-2737.	5.2	9
28	Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1105-1123.	4.9	9
29	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 160-165.	0.9	8
30	Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 5319-5327.	4.1	8
31	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. <i>Blood</i> , 2017, 130, 847-847.	1.4	8
32	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2020, 13, 32-39.	0.9	7
33	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 101.e1-101.e1.	1.2	7
34	Concurrent juvenile myelomonocytic leukemia and T-cell lymphoblastic lymphoma with a shared missense mutation in <i>NRAS</i> . <i>Pediatric Blood and Cancer</i> , 2014, 61, 946-948.	1.5	6
35	Augmenting Non-Myeloablative BMT with Pcty Using Thiotepa or 400 Cgy TBI Improves Engraftment in Patients with Transfusion Dependent Thalassemia: Results of a Haploidentical Transplant Consortium for Hemoglobinopathies (ICHH). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S310-S311.	2.0	6
36	Parent and Guardian Knowledge of Hematopoietic Cell Transplantation as a Treatment Option for Sickle Cell Disease. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 187-193.	0.6	6

#	ARTICLE	IF	CITATIONS
37	Single Nucleotide Gene Polymorphisms (SNP) in the Gamma Block of the Major Histocompatibility Complex (MHC) Are Independent Risk Factors for Severe Acute Graft Versus Host Disease (GVHD) in Unrelated Donor Hematopoietic Cell Transplantation (HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S326-S327.	2.0	5
38	Letermovir for Secondary Cytomegalovirus (CMV) Prophylaxis in a Pediatric Stem Cell Transplant Patient. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S282-S283.	2.0	5
39	The treatment of adolescents and young adults with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 18-26.	1.3	5
40	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2826-2833.	2.4	5
41	Lymphocyte cytosolic protein 1 (L-plastin) I232F mutation impairs granulocytic proliferation and causes neutropenia. <i>Blood Advances</i> , 2022, 6, 2581-2594.	5.2	5
42	Balloon Kyphoplasty for Managing Intractable Pain in Pediatric Pathologic Vertebral Fractures. <i>Journal of Pediatric Orthopaedics</i> , 2017, 37, e286-e291.	1.2	4
43	Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2522-2526.	2.0	4
44	Paediatric haematologists' attitudes regarding haematopoietic cell transplantation as treatment for sickle cell disease. <i>British Journal of Haematology</i> , 2020, 188, 976-984.	2.5	4
45	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 3880-3880.	1.4	4
46	Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2015, 8, 115-124.	0.9	3
47	Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 776-781.	2.0	3
48	Safety of allogeneic hematopoietic stem cell transplantation in beta-thalassemia patients with chronic hepatitis C infections treated at a pediatric center. <i>Pediatric Transplantation</i> , 2019, 23, e13520.	1.0	3
49	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 917.e1-917.e9.	1.2	3
50	Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations. <i>Blood</i> , 2015, 126, 740-740.	1.4	3
51	Prognostic Effect of Bone Marrow (BM) and Peripheral Blood Stem Cell (PBSC) Donor Cell Subsets on Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes. <i>Blood</i> , 2016, 128, 660-660.	1.4	3
52	Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S55.	2.0	2
53	No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial. <i>Blood</i> , 2019, 134, 146-146.	1.4	2
54	Defining Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome.. <i>Blood</i> , 2012, 120, 3042-3042.	1.4	2

#	ARTICLE	IF	CITATIONS
55	HLA-Mismatch Is Associated with Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A Cibmtr Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S25-S26.	2.0	1
56	Liver Transplantation for Hepatocellular Carcinoma in Young Adults: A United Network for Organ Sharing Study. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 286-293.	1.3	1
57	Brachial plexus chloroma as a presenting feature of relapse in a child with KMT2A-rearranged acute lymphoblastic leukemia, a case report. <i>Pediatric Hematology and Oncology</i> , 2021, 38, 179-183.	0.8	1
58	Improved Clinical Outcomes with Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized, Multicenter Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, S33-S34.	1.2	1
59	Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series. <i>Pediatric Hematology and Oncology</i> , 2022, 39, 80-82.	0.8	1
60	Related and Unrelated Donor Transplantation for β^2 Thalassemia Major: Results of an International Survey. <i>Blood</i> , 2018, 132, 308-308.	1.4	1
61	Omission of Methotrexate Doses Due to Toxicity Does Not Influence the Incidence of Gvhd, Relapse, or Survival. <i>Blood</i> , 2012, 120, 4189-4189.	1.4	1
62	Mycophenolate Mofetil Is a Suitable Substitute for Methotrexate for Graft Versus Host Disease Prevention in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Sibling Donors. <i>Blood</i> , 2012, 120, 1952-1952.	1.4	1
63	Successful Treatment with ALVR105 for Disseminated Adenovirus Infection in an Infant after Allogeneic Hematopoietic Cell Transplantation: A Case Report. <i>Blood</i> , 2021, 138, 4865-4865.	1.4	1
64	Can We Predict Hemorrhagic Cystitis Based on BK Viremia?. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1137-1138.	2.0	0
65	Evaluation of Ciprofloxacin in the Treatment of BK VIRUS-Associated Hemorrhagic Cystitis in Hematopoietic CELL Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S169-S170.	2.0	0
66	Acute GVHD in AML and MDS Patients Receiving Matched Related Donor (MRD) Reduced-Intensity Conditioning Allogeneic Hematopoietic Progenitor Cell Transplant (RIC-AHPCT) Correlates with Major Histocompatibility Complex Class I-Related Molecule A (MICA) Gene Polymorphisms,. <i>Blood</i> , 2011, 118, 4072-4072.	1.4	0
67	Racial Differences in Prognostic Factors and Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant. <i>Blood</i> , 2012, 120, 2020-2020.	1.4	0
68	Long Term Survival After High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation in Metastatic Breast Cancer.. <i>Blood</i> , 2012, 120, 3072-3072.	1.4	0
69	Risk Factors for Vancomycin Resistant Enterococcus (VRE) Infection and Its Influence On Survival After Allogeneic Hematopoietic Progenitor Cell Transplantation (aHPCT). <i>Blood</i> , 2012, 120, 4147-4147.	1.4	0
70	Long-Term Follow-up of a Randomized Trial Comparing Cyclosporine and Short Course Methotrexate with Cyclosporine and Mycophenolate Mofetil for Graft Versus Host Disease Prophylaxis in Myeloablative HLA-Identical Sibling Hematopoietic Cell Transplantation.. <i>Blood</i> , 2012, 120, 3073-3073.	1.4	0
71	Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Incidence, Risk Factors, and Impact On Survival. <i>Blood</i> , 2012, 120, 4481-4481.	1.4	0
72	Long-Term Outcome Of Adolescents and Young Adults (AYA) After Autologous Transplantation For Lymphoma; Single Center Experience With Bu-CY-VP16 Conditioning Therapy. <i>Blood</i> , 2013, 122, 4644-4644.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Long-Term Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 5534-5534.	1.4	0
74	Comparative Effectiveness of Fludarabine and Busulfan Versus Fludarabine and 400 cGy Total Body Irradiation Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation for AML/MDS. <i>Blood</i> , 2015, 126, 1920-1920.	1.4	0
75	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 4666-4666.	1.4	0
76	Germline and Somatic Genetic Characterization of Shwachman-Diamond Syndrome. <i>Blood</i> , 2016, 128, 2681-2681.	1.4	0
77	A Step Toward Comprehensive Transplant Solutions for Aplastic Anemia. <i>Transplantation</i> , 2021, 105, 955-957.	1.0	0
78	Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2021, 138, 99-99.	1.4	0
79	Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S130-S131.	1.2	0